From Yahoo Finance: 2025-04-25 13:21:00

NovoCure’s stock saw a slight increase after reporting strong first-quarter results and receiving European CE Mark approval for OptuneLua in treating lung cancer. The company’s Phase 3 trial for pancreatic cancer also showed promising results, driving revenue growth. Despite a $34 million loss this quarter, NovoCure’s revenue grew by 12% year over year. The company’s stock is seen as a solid pick for those with a higher risk tolerance. However, it wasn’t included in the Motley Fool’s list of top 10 stocks to buy now. NovoCure continues to show potential for growth and market expansion.



Read more at Yahoo Finance: Why NovoCure Stock Skyrocketed This Week